Vandria SA bags CHF18m in Series A financing
Lausanne-based Vandria SA has cashed in CHF18m in a Series A financing led by ND Capital to drive clinical development of VNA-318.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1118 entries already.
Entries by Thomas Gabrielczyk
Antabio SAS raises €25 m in Series B financing
/in News/by Thomas Gabrielczyk<a title="http://www.b3cnewswire.com/PRT/link.php?click=1619-2-24039-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000" target="_blank" rel="nofollow noopener" href="http://www.b3cnewswire.com/PRT/link.php?click=1619-2-24039-8B20BDBA70E6BDF1B5F7FEECBC3EA611CB7D4F450000">Antibiotics specialist Antabio SAS</a> has raised €25m in a Series B financing round with subscriptions from the AMR Action Fund, the EIC Fund and from […]
Production process for cell-based coffee published
/in News/by Thomas GabrielczykScientists led by Heiko Rischer from the Finnish research centre VTT have published the proof of concept for cell-based coffee production.
Germany blocks deregulation of NGT breeds
/in News/by Thomas GabrielczykAt the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the <link https://data.consilium.europa.eu/doc/document/ST-16443-2023-INIT/en/pdf>adapted version of the EU Commission’s draft regulation</link> on new genomic […]
Cathera SA closes Series B round at €42m
/in News/by Thomas GabrielczykSorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.<br /> <br />
UK publishes £2bn vision for engineering biology
/in News/by Thomas GabrielczykOn the occasion of SynbiTECH in London, British Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.
Valnevas Lyme vaccine trial complets recruitment
/in News/by Thomas GabrielczykPfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.
Unveiling prostate cancer's Achilles' heel
/in News/by Thomas GabrielczykResearchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.
$30m for genetic medicine advancements
/in News/by Thomas GabrielczykEligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.
Takeover in ADC space: Abbvie snags ImmunoGen
/in News/by Thomas GabrielczykAbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.